Who owns AVALO THERAPEUTICS ORD?
- Ticker: AVTX
- CUSIP Number: 05338f306
Tip: Access positions for across all investors
Analyze quarterly positions in Avalo Therapeutics Ord with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Avalo Therapeutics Ord stock
Who bought or sold AVALO THERAPEUTICS ORD this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| BVF | 1.4M | $17M | 32% | Sep 2025 |
|
| Nantahala Capital Management | 1.2M | $22M | 0% | Dec 2025 |
|
| OrbiMed Advisors | 1.2M | $22M | -12% | Dec 2025 |
|
| Affinity Asset Advisors | 1.1M | $19M | 4% | Dec 2025 |
|
| Caligan Partners | 882k | $16M | 6% | Dec 2025 |
|
| Balyasny Asset Management | 817k | $10M | 100% | Sep 2025 |
|
| Vanguard Group | 804k | $15M | 16% | Dec 2025 |
|
| RA Capital Management | 663k | $8.4M | -29% | Sep 2025 |
|
| Point72 Asset Management | 628k | $11M | -40% | Dec 2025 |
|
| Silverarc Capital Management | 524k | $9.5M | -27% | Dec 2025 |
|
| Marshall Wace | 508k | $9.2M | 806% | Dec 2025 |
|
| Citadel Advisors | 493k | $6.3M | 100% | Sep 2025 |
|
| Commodore Capital | 483k | $8.8M | 0% | Dec 2025 |
|
| TCG Crossover Management | 483k | $8.8M | 0% | Dec 2025 |
|
| UBS Group | 478k | $8.6M | 957% | Dec 2025 |
|
| Jennison Associates | 476k | $8.6M | 100% | Dec 2025 |
|
| Soleus Capital Management | 442k | $8.0M | 100% | Dec 2025 |
|
| Patient Square Capital | 312k | $5.7M | 212% | Dec 2025 |
|
| Caption Management | 303k | $5.5M | 100% | Dec 2025 |
|
| Susquehanna International | 296k | $5.4M | 165% | Dec 2025 |
|
| BlackRock | 290k | $5.3M | 88% | Dec 2025 |
|
| Boxer Capital Management | 275k | $5.0M | 120% | Dec 2025 |
|
| Velan Capital Investment Management | 264k | $4.8M | 0% | Dec 2025 |
|
| Adage Capital Partners GP | 259k | $3.3M | 100% | Sep 2025 |
|
| Boothbay Fund Management | 219k | $4.0M | -4% | Dec 2025 |
|
| Ameriprise Financial | 218k | $4.0M | 2% | Dec 2025 |
|
| Jain Global | 217k | $3.9M | 100% | Dec 2025 |
|
| Bnp Paribas Arbitrage, Snc | 198k | $3.6M | 3954840% | Dec 2025 |
|
| SummitTX Capital | 196k | $3.6M | 100% | Dec 2025 |
|
| Nan Fung Trinity | 189k | $3.4M | 100% | Dec 2025 |
|
| Jane Street | 179k | $3.2M | 100% | Dec 2025 |
|
| Geode Capital Management | 166k | $3.0M | 59% | Dec 2025 |
|
| Superstring Capital Management | 153k | $2.8M | -18% | Dec 2025 |
|
| Deutsche Bank Aktiengesellschaft | 150k | $2.7M | 100% | Dec 2025 |
|
| Perceptive Advisors | 140k | $1.8M | 0% | Sep 2025 |
|
| Millennium Management | 137k | $1.7M | 100% | Sep 2025 |
|
| Stempoint Capital | 136k | $2.5M | 100% | Dec 2025 |
|
| Moody Aldrich Partners | 133k | $2.4M | 100% | Dec 2025 |
|
| Dr. Jeffrey R. Jay, M.D. | 125k | $2.3M | 100% | Dec 2025 |
|
| Barclays | 106k | $1.9M | 100% | Dec 2025 |
|
| Standard Life Aberdeen | 95k | $1.7M | 31% | Dec 2025 |
|
| Ikarian Capital | 89k | $1.6M | -44% | Dec 2025 |
|
| State Street Corporation | 79k | $1.4M | 74% | Dec 2025 |
|
| DLD Asset Management | 76k | $1.4M | -50% | Dec 2025 |
|
| Sio Capital Management | 72k | $917k | 0% | Sep 2025 |
|
| Goldman Sachs Group | 65k | $1.2M | 100% | Dec 2025 |
|
| Qube Research & Technologies | 65k | $1.2M | 100% | Dec 2025 |
|
| Seven Fleet Capital Management | 63k | $1.2M | 100% | Dec 2025 |
|
| 683 Capital Management | 57k | $1.0M | 100% | Dec 2025 |
|
| Quadrature Capital | 53k | $963k | 100% | Dec 2025 |
|
| Woodline Partners | 52k | $945k | 100% | Dec 2025 |
|
| Atom Investors | 51k | $930k | 100% | Dec 2025 |
|
| Two Sigma Investments | 49k | $626k | 282% | Sep 2025 |
|
| Walleye Trading Advisors | 42k | $757k | -7% | Dec 2025 |
|
| Artia Global Partners | 42k | $755k | 100% | Dec 2025 |
|
| Squarepoint Ops | 41k | $742k | 100% | Dec 2025 |
|
| XTX Topco | 41k | $735k | 190% | Dec 2025 |
|
| ExodusPoint Capital Management | 32k | $586k | 100% | Dec 2025 |
|
| Northern Trust | 32k | $585k | 73% | Dec 2025 |
|
| HighVista Strategies | 28k | $353k | 100% | Sep 2025 |
|
| Springbok Capital Management | 25k | $313k | 100% | Sep 2025 |
|
| OMERS Administration Corporation | 20k | $356k | 100% | Dec 2025 |
|
| Renaissance Technologies | 18k | $332k | -81% | Dec 2025 |
|
| Belvedere Trading | 17k | $317k | 100% | Dec 2025 |
|
| Hudson Bay Capital Management | 17k | $305k | 100% | Dec 2025 |
|
| Envestnet Asset Management | 16k | $291k | 100% | Dec 2025 |
|
| Persistent Asset Partners | 15k | $274k | 100% | Dec 2025 |
|
| Jump Financial | 13k | $238k | 100% | Dec 2025 |
|
| Tower Research Capital | 8.7k | $159k | 33504% | Dec 2025 |
|
| Us Bancorp | 2.7k | $50k | 100% | Dec 2025 |
|
| PFS Partners | 2.0k | $36k | 100% | Dec 2025 |
|
| Jpmorgan Chase & Co | 1.6k | $20k | 100% | Sep 2025 |
|
| Acadian Asset Management | 1.5k | $26k | 100% | Dec 2025 |
|
| Activest Wealth Management | 1.00 | $18.000000 | 0% | Dec 2025 |
|
| Key FInancial | 1.00 | $18.000000 | 0% | Dec 2025 |
|
| Group One Trading | 1.00 | $18.000000 | -100% | Dec 2025 |
|
| Parallel Advisors | 1.00 | $18.000000 | 0% | Dec 2025 |
|
| Advisor Group Holdings | 1.00 | $18.000000 | -50% | Dec 2025 |
|
Who sold out of Avalo Therapeutics Ord?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Ally Bridge Group | Sep 2025 | 178k | $2.3M |
| Deep Track Capital | Sep 2025 | 145k | $1.8M |
| Exome Asset Management | Sep 2025 | 100k | $1.3M |
| Adviser Investments | Sep 2025 | 87k | $1.1M |
| Cantor Fitzgerald, L. P. | Sep 2025 | 85k | $1.1M |
| Landscape Capital Management | Sep 2025 | 33k | $424k |
| ADAR1 Capital Management | Sep 2025 | 32k | $412k |
| Birchview Capital | Sep 2025 | 31k | $394k |
| Dimensional Fund Advisors | Sep 2025 | 11k | $143k |
| Simplex Trading | Sep 2025 | 748.00 | $9.0k |
| SBI Securities | Sep 2025 | 23.00 | $292.001100 |
| Efficient Wealth Management | Sep 2025 | 5.00 | $0 |